Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, today announced that it has secured $2.8 million (£2.1 million) in funding. The investment was led by US life sciences specialist BroadOak Capital Partners, with the company's founding investor, the Roslin Foundation, also participating.
The funding will accelerate Axol's next phase of growth, supporting the expansion of its US operations and commercial presence. It will also enable development of enhanced neuroscience, ophthalmology, and cardiovascular disease models, and cell manufacturing scale-up at its Roslin Innovation Centre base, in response to increasing global customer demand for more human-relevant in vitro disease models.
Axol Bioscience develops and supplies high-quality functional iPSC-derived cells, reagents, and specialist services to pharmaceutical, biotech, CROs, and academic institutions worldwide. Axol has recently established itself as a leader in provision of physiologically relevant iPSC-derived models for neurodegenerative disorders including Huntington's disease and sporadic amyotrophic lateral sclerosis (ALS/MND), addressing significant unmet needs in neurodegenerative disease research.
We're proud to partner with BroadOak, a global leader in life sciences investing. Their expertise and support, alongside our long-term partner Roslin Foundation, reflects confidence in our long-term vision, team, products, and technology as we scale operations and expand internationally."
Liam Taylor, CEO, Axol Bioscience
"Following Axol's 45 % revenue growth in 2025 and 36 % in 2024, this funding allows us to strengthen our US operations and expand manufacturing capacity at our Edinburgh site, ensuring we can continue to meet increasing global demand," added Oliver Richardson, CFO of Axol Bioscience.
"Axol is a leader in their space and is well positioned as global regulators actively usher in the adoption of cell-based models. We are excited to be partnering with Liam, Oli, and the entire Axol team to support their next phase of growth," said Daniel Friedman, Managing Director at BroadOak Capital Partners.
This funding follows a period of strong commercial and strategic momentum for Axol, including sustained double-digit revenue growth, the expansion of its portfolio of physiologically relevant iPSC-derived disease models, and continued investment in manufacturing and quality systems at its Edinburgh facility. Over the past year, the company has also strengthened its relationships with global pharmaceutical partners and advanced its US market presence, further reinforcing Axol's position as a trusted supplier of human-relevant in vitro models to the life sciences industry.
Single-cell analysis illuminates myeloma immune landscape